Cargando…
Persistence to anti-cancer treatments in the stationary to proliferating transition
The heterogeneous responses of clonal cancer cells to treatment is understood to be caused by several factors, including stochasticity, cell-cycle dynamics, and different micro-environments. In a tumor, cancer cells may encounter fluctuating conditions and transit from a stationary culture to a prol...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224467/ https://www.ncbi.nlm.nih.gov/pubmed/27801609 http://dx.doi.org/10.1080/15384101.2016.1248006 |
_version_ | 1782493364628750336 |
---|---|
author | Pearl Mizrahi, Sivan Gefen, Orit Simon, Itamar Balaban, Nathalie Q. |
author_facet | Pearl Mizrahi, Sivan Gefen, Orit Simon, Itamar Balaban, Nathalie Q. |
author_sort | Pearl Mizrahi, Sivan |
collection | PubMed |
description | The heterogeneous responses of clonal cancer cells to treatment is understood to be caused by several factors, including stochasticity, cell-cycle dynamics, and different micro-environments. In a tumor, cancer cells may encounter fluctuating conditions and transit from a stationary culture to a proliferating state, for example this may occur following treatment. Here, we undertake a quantitative evaluation of the response of single cancerous lymphoblasts (L1210 cells) to various treatments administered during this transition. Additionally, we developed an experimental system, a “Mammalian Mother Machine,” that tracks the fate of thousands of mammalian cells over several generations under transient exposure to chemotherapeutic drugs. Using our developed system, we were able to follow the same cell under repeated treatments and continuously track many generations. We found that the dynamics of the transition between stationary and proliferative states are highly variable and affect the response to drug treatment. Using cell-cycle markers, we were able to isolate a subpopulation of persister cells with distinctly higher than average survival probability. The higher survival rate encountered with cell-cycle phase specific drugs was associated with a significantly longer time-till-division, and was reduced by a non cell-cycle specific drug. Our results suggest that the variability of transition times from the stationary to the proliferating state may be an obstacle hampering the effectiveness of drugs and should be taken into account when designing treatment regimens. |
format | Online Article Text |
id | pubmed-5224467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-52244672017-01-15 Persistence to anti-cancer treatments in the stationary to proliferating transition Pearl Mizrahi, Sivan Gefen, Orit Simon, Itamar Balaban, Nathalie Q. Cell Cycle Report The heterogeneous responses of clonal cancer cells to treatment is understood to be caused by several factors, including stochasticity, cell-cycle dynamics, and different micro-environments. In a tumor, cancer cells may encounter fluctuating conditions and transit from a stationary culture to a proliferating state, for example this may occur following treatment. Here, we undertake a quantitative evaluation of the response of single cancerous lymphoblasts (L1210 cells) to various treatments administered during this transition. Additionally, we developed an experimental system, a “Mammalian Mother Machine,” that tracks the fate of thousands of mammalian cells over several generations under transient exposure to chemotherapeutic drugs. Using our developed system, we were able to follow the same cell under repeated treatments and continuously track many generations. We found that the dynamics of the transition between stationary and proliferative states are highly variable and affect the response to drug treatment. Using cell-cycle markers, we were able to isolate a subpopulation of persister cells with distinctly higher than average survival probability. The higher survival rate encountered with cell-cycle phase specific drugs was associated with a significantly longer time-till-division, and was reduced by a non cell-cycle specific drug. Our results suggest that the variability of transition times from the stationary to the proliferating state may be an obstacle hampering the effectiveness of drugs and should be taken into account when designing treatment regimens. Taylor & Francis 2016-11-01 /pmc/articles/PMC5224467/ /pubmed/27801609 http://dx.doi.org/10.1080/15384101.2016.1248006 Text en © 2016 The Author(s). Published with license by Taylor & Francis. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Report Pearl Mizrahi, Sivan Gefen, Orit Simon, Itamar Balaban, Nathalie Q. Persistence to anti-cancer treatments in the stationary to proliferating transition |
title | Persistence to anti-cancer treatments in the stationary to proliferating transition |
title_full | Persistence to anti-cancer treatments in the stationary to proliferating transition |
title_fullStr | Persistence to anti-cancer treatments in the stationary to proliferating transition |
title_full_unstemmed | Persistence to anti-cancer treatments in the stationary to proliferating transition |
title_short | Persistence to anti-cancer treatments in the stationary to proliferating transition |
title_sort | persistence to anti-cancer treatments in the stationary to proliferating transition |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224467/ https://www.ncbi.nlm.nih.gov/pubmed/27801609 http://dx.doi.org/10.1080/15384101.2016.1248006 |
work_keys_str_mv | AT pearlmizrahisivan persistencetoanticancertreatmentsinthestationarytoproliferatingtransition AT gefenorit persistencetoanticancertreatmentsinthestationarytoproliferatingtransition AT simonitamar persistencetoanticancertreatmentsinthestationarytoproliferatingtransition AT balabannathalieq persistencetoanticancertreatmentsinthestationarytoproliferatingtransition |